Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for ADT-Induced Insulin Resistance in Prostate Cancer
NCT05098327Phase 3Withdrawn
- Sponsor
- University at Buffalo
- Start
- Aug 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pioglitazone in insulin resistance (IR), sponsored by University at Buffalo. Planned start Aug 2021; status: withdrawn.
02
Drugs
pioglitazone
03
Conditions
insulin resistance (IR)
Beyond the preview
Go deeper on NCT05098327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098327.